IDEXX Laboratories, Inc. 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2006. IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for the veterinary market, as well as for food and water testing. The company operates through three primary reportable segments: the Companion Animal Group (CAG), Water quality products, and the Production Animal Segment (PAS). A smaller Dairy segment is reported in "Other." In January 2007, the company acquired the Critical Care Division of Osmetech plc, adding an OPTI Medical Systems segment for human point-of-care diagnostics.
Key Financial Metrics (Year Ended Dec 31, 2006)
| Metric | 2006 | 2005 | Change |
|---|---|---|---|
| Total Revenue | $739.1 million | $638.1 million | +15.8% |
| Gross Profit | $379.5 million | $322.9 million | +17.5% |
| Gross Margin | 51.3% | 50.6% | +0.7 pts |
| Operating Income | $127.9 million | $115.3 million | +10.9% |
| Net Income | $93.7 million | $78.3 million | +19.7% |
| Diluted EPS | $2.84 | $2.30 | +23.5% |
| Cash & Investments | $96.7 million | $132.7 million | -27.1% |
| Working Capital | $177.5 million | $192.7 million | -7.9% |
| Total Debt | $7.1 million | $0.6 million | Significant Increase |
Note: The increase in debt is primarily due to a mortgage assumed in May 2006 for the purchase of the company's Westbrook, Maine headquarters facility.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 16.4% increase in the Companion Animal Group (CAG) and a 31.1% increase in the Production Animal Segment (PAS). CAG growth was fueled by higher sales of instruments, consumables, and laboratory services. PAS growth was driven by livestock diagnostics, particularly in Europe.
- Accounting Change: The company adopted SFAS No. 123(R) on January 1, 2006, requiring the expensing of share-based compensation. This resulted in an additional $10.7 million in expenses, negatively impacting operating margins by approximately 1% compared to the prior year.
- Segment Performance:
- CAG: Revenue of $606.3 million; Operating Income of $100.8 million.
- Water: Revenue of $58.5 million; Operating Income of $25.8 million.
- PAS: Revenue of $58.9 million; Operating Income of $16.2 million.
- Acquisitions: The company spent $25.2 million net cash on acquisitions in 2006, including veterinary reference laboratories in the U.S., Canada, and South Africa, and a practice information management software business.
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Strategy: Management expects continued growth through the integration of acquisitions and the launch of new products, specifically the Catalyst Dx chemistry analyzer and SNAPshot Dx immunoassay platform, both targeted for commercial availability in 2008.
- Regulatory Risks:
- U.K. Water Testing: A proposal by the U.K. Drinking Water Inspectorate to discontinue mandatory Cryptosporidia testing could eliminate approximately $2.9 million in annual sales of Filta-Max products in England and Wales.
- Pharmaceuticals: One veterinary pharmaceutical product is sold under FDA regulatory discretion. If a competitor's product is approved or raw material inventory is depleted (expected late 2008/early 2009), sales of this product ($11.9 million in 2006) may need to be discontinued.
- Supply Chain Risks: The company relies on single-source suppliers for critical components, including VetTest slides (Ortho) and VetAutoread analyzers (QBC Diagnostics). Minimum purchase obligations total over $74 million through 2020.
- Unusual Items: The effective tax rate decreased to 28.4% in 2006 (from 34.2% in 2005) largely due to the favorable resolution of an IRS audit for 2003-2004 and the release of valuation allowances on international deferred tax assets.
Key Facts for Investor Verification
- Supplier Concentration: Verify the stability of supply agreements with Ortho-Clinical Diagnostics (VetTest slides) and QBC Diagnostics (VetAutoread), which represent significant minimum purchase commitments.
- Regulatory Exposure: Monitor the status of the U.K. Cryptosporidia testing regulation proposal and the FDA approval timeline for the company's new veterinary pharmaceutical product to replace the current one.
- Share-Based Compensation: Assess the ongoing impact of SFAS 123(R) on future earnings, as the company shifted to a mix of restricted stock units and options in 2006.
- Acquisition Integration: Track the integration and profitability of recent acquisitions, particularly the veterinary reference laboratories and the pending acquisition of Institut Pourquier (announced Jan 2007).
- Capital Allocation: Review the company's capital spending plan, which includes approximately $65 million for 2007, largely for the renovation and expansion of the Westbrook, Maine headquarters.